T-cell-activation inhibitors in rheumatoid arthritis

BioDrugs

Volumn 17, Issue 4, 2003, Pages 263-270

  Lorenz, Hanns Martin ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; BELATACEPT; CD4 ANTIGEN; CHLOROQUINE; CYCLOSPORIN A; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIHYDROOROTATE DEHYDROGENASE; ETANERCEPT; HLA DR ANTIGEN; HLA DR4 ANTIGEN; HYBRID PROTEIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6 RECEPTOR; IR 501; KELIXIMAB; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY 4162W94; OKT 4; PLACEBO; SALAZOSULFAPYRIDINE; T LYMPHOCYTE ACTIVATION INHIBITOR; T LYMPHOCYTE RECEPTOR BETA CHAIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALOPECIA; BONE DESTRUCTION; CARTILAGE DEGENERATION; CELL SPECIFICITY; CHRONIC INFLAMMATION; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPEPSIA; ECCHYMOSIS; ENZYME INHIBITION; GASTROENTERITIS; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; LEUKOCYTOCLASTIC VASCULITIS; LIVER NECROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG TUBERCULOSIS; LYMPHOCYTE FUNCTION; LYMPHOCYTOPENIA; MUSCLE CRAMP; NAUSEA; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOMES RESEARCH; PANCREATITIS; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; RHEUMATOID ARTHRITIS; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE ACTIVATION; TREATMENT PLANNING; TREMOR; VACCINATION; VASCULITIS; VASODILATATION;

ADJUVANTS, IMMUNOLOGIC; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; LYMPHOCYTE ACTIVATION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 0043235644     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317040-00005     Document Type: Review

References (64)

1. Sokka T, Kautiainen H, Mottonen T, et al. Work disability in rheumatoid arthritis 10 years after the diagnosis. J Rheumatol 1999; 26: 1681-5
2. Lipsky PE, van der Heijde DM, St Clair EW, et al. 102 week clinical and radiological results from the ATTRACT trial: a 2 year, randomized controlled phase III trial of infliximab in patients with active RA despite MTX [abstract]. Arthritis Rheum 2000; 43: S269
3. Nepom GT, Hansen JA, Nepom BS. The molecular basis for HLA class II associations with rheumatoid arthritis. J Clin Immunol 1987; 7: 1-7
4. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978; 298: 869-71
5. Weyand CM, Hicok KC, Conn DL, et al. The influence of HLA-DRBI genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992; 117: 801-6
6. Stamenkovic I, Stegagno M, Wright KA, et al. Clonal dominance among T-lymphocyte infiltrates in arthritis. Proc Natl Acad Sci U S A 1988; 85: 1179-83
7. Jenkins RN, Nikaein A, Zimmermann A, et al. T cell V beta gene bias in rheumatoid arthritis. J Clin Invest 1993; 92: 2688-701
8. Gudmundsson S, Ronnelid J, Karlsson-Parra A, et al. T-cell receptor V-gene usage in synovial fluid and synovial tissue from RA patients. Scand J Immunol 1992; 36: 681-8
9. Vanderborght A, De KF, Geusens P, et al. Dynamic T cell receptor clonotype changes in synovial tissue of patients with early rheumatoid arthritis: effects of treatment with cyclosporin A (Neoral). J Rheumatol 2002; 29: 416-26
10. Ruckemann K, Fairbanks LD, Carrey EA, et al. Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998; 273: 21682-92
11. Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase I1 study. Arthritis Rheum 1995; 38: 1595-603
12. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353: 259-66
13. Scott DL, Smolen JS, Kalden JR, et al. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis 2001; 60: 913-23
14. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate: Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 2542-50
15. Cohen S, Cannon GW, Schiff M. et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate: Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum 2001; 44: 1984-92
16. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 726-33
17. Breedveld FC. Is there a place for leflunomide in the treatment of rheumatoid arthritis? Lancet 2001; 358: 1198-9
18. Legras A, Bergemer-Fouquet AM, Jonville-Bera AP. Fatal hepatitis with leflunomide and itraconazole. Am J Med 2002; 113: 352-3
19. Wolfe F. Low rates of serious liver toxicity to leflunomide (LEF) and methotrexate (MTX): a longitudinal surveillance study of 14,997 LEF or MTX exposures in RA [abstract]. Arthritis Rheum 2002; 46: S375
20. Cannon GW, Schiff M, Strand V, et al. Hepatic adverse events and other toxicity during treatment with leflunomide, methotrexate, other disease modifying antirheumatic drugs, and combination DMARD therapy: comparison to NSAIDs alone and adjustment for comorbidities [abstract]. Arthritis Rheum 2002; 46: S166
21. Rozman B, Praprotnik S, Logar D, et al. Leflunomide and hypertension. Ann Rheum Dis 2002; 61: 567-9
22. Prokopowitsch AS, Diogenes AHM, Borges CT, et al. Leflunomide induces progressive increase in rheumatoid arthritis lipid profile [abstract]. Arthritis Rheum 2002; 46: S164
23. Kiely PD, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology 2002; 41: 631-7
24. Knoerzer DB, Karr RW, Schwartz BD. Collagen-induced arthritis in the BB rat: prevention of disease by treatment with CTLA4-Ig. J Clin Invest 1995; 96: 987-93
25. Shimoyama Y, Nagafuchi H, Suzuki N, et al. Synovium infiltrating T cells induce excessive synovial cell function through CD28/B7 pathway in patients with rheumatoid arthritis. J Rheumatol 1999; 26: 2094-101
26. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA4-Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 2002; 46: 1470-9
27. Kremer J, Westhovens R, Leon M, et al. A phase 2B multi-center, randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of two different doses of CTLA4-Ig administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate [abstract]. Arthritis Rheum 2002; 46: S203
28. Weinblatt M, Schiff M, Goldman M, et al. A pilot, multi-center, randomized, double-blind, placebo-controlled study of a co-stimulation blocker CTLA4-Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis [abstract]. Arthritis Rheum 2002; 46: S204
29. Moreland LW, Heck LWJ, Koopman WJ, et al. V beta 17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study. J Rheumatol 1996; 23: 1353-62
30. Moreland LW, Morgan EE, Adamson TC, et al. T cell receptor peptide vaccination in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1919-29
31. Matsumoto AK, Moreland LW, Strand V, et al. Results of phase IIb rheumatoid arthritis clinical trial using T-cell receptor peptides [abstract]. Arthritis Rheum 1999; 42: S117
32. Panayi GS, Choy EHS, Emery P, et al. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 monoclonal antibody in rheumatoid arthritis [abstract]. Arthritis Rheum 1998; 41: S56
33. Choy EH, Panayi GS, Emery P, et al. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis: a randomized placebo-controlled trial. Rheumatology 2002; 41: 1142-8
34. Levy R, Weisman M, Wiesenhutter C, et al. Results of a placebo-controlled, multicenter trial using a primatized non-depleting, anti-CD4 monoclonal anti-body in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39: S122
35. Mason U, Aldrich J, Breedveld F, et al. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol 2002; 29: 220-9
36. Halloran PF. Molecular mechanisms of new immunosuppressants. Clin Transplant 1996; 10: 118-23
37. Jin L, Harrison SC. Crystal structure of human calcineurin complexed with cyclosporin A and human cyclophilin. Proc Natl Acad Sci U S A 2002; 99: 13522-6
38. Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992; 13: 136-42
39. Tomono M, Toyoshima K, Ire M, et al. Calcineurin is essential for DNA synthesis in Swiss 3T3 fibroblasts. Biochem J 1996; 317: 675-80
40. Wolf G, Thaiss F, Stahl RA. Cyclosporine stimulates expression of transforming growth factor-beta in renal cells: possible mechanism of cyclosporines antiproliferative effects. Transplantation 1995; 60: 237-41
41. Yoon CH, Cho ML, Min SY, et al. Cyclosporine A inhibits vascular endothelial growth factor production in cultured rheumatoid synovial fibroblasts [abstract]. Ann Rheum Dis 2000; 59: 188
42. Cho ML, Cho CS, Min SY, et al. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. Arthritis Rheum 2002; 46: 1202-9
43. Cho ML, Kim WU, Min SY, et al. Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor α production by rheumatoid synoviocytes. Arthritis Rheum 2002; 46: 42-51
44. Al-Daraji WI, Grant KR, Ryan K, et al. Localization of calcineurin/NFAT in human skin and psoriasis and inhibition of calcineurin/NFAT activation in human keratinocytes by cyclosporin A. J Invest Dermatol 2002; 118: 779-88
45. Spisani S, Fabbri E, Rizzuti O, et al. Inhibition of neutrophil responses by cyclosporine [abstract]. Ann Rheum Dis 2000; 59: 122
46. Adams DH, Wang LF, Neuberger JM, et al. Inhibition of leukocyte chemotaxis by immunosuppressive agents: specific inhibition of lymphocyte chemotaxis by cyclosporine. Transplantation 1990; 50: 845-50
47. Awumey EM, Moonga BS, Sodam BR, et al. Molecular and functional evidence for calcineurin-A alpha and beta isoforms in the osteoclast: novel insights into cyclosporin A action on bone resorption. Biochem Biophys Res Commun 1999; 254: 248-52
48. Smith CS, Ortega G, Parker L, et al. Cyclosporine A blocks induction of tumor necrosis factor-alpha in human B-lymphocytes. Biochem Biophys Res Commun 1994; 204: 383-90
49. Remick DG, Nguyen DT, Eskandari MK, et al. Cyclosporine A inhibits TNF production without decreasing TNF mRNA levels. Biochem Biophys Res Commun 1989; 161: 551-5
50. van Rijthoven AW, Dijkmans BA, Goei The HS, et al. Cyclosporin treatment for rheumatoid arthritis: a placebo controlled, double blind, multicentre study. Ann Rheum Dis 1986; 45: 726-31
51. Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis 1988; 47: 127-33
52. Landewe RB, Goei The HS, van Rijthoven AW, et al. A randomized, double-blind. 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994; 37: 637-43
53. Drosos AA, Voulgari PV, Papadopoulos IA, et al. Cyclosporine A in the treatment of early rheumatoid arthritis: a prospective, randomized 24-month study. Clin Exp Rheumatol 1998; 16: 695-701
54. Airman RD, Schiff M, Kopp EJ. Cyclosporine A in rheumatoid arthritis: randomized, placebo controlled dose finding study. J Rheumatol 1999; 26: 2102-9
55. Marra CA, Esdaile JM, Guh D, et al. The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. Arthritis Rheum 2001; 45: 240-5
56. Anderson IF, Helve T, Hannonen P, et al. Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporine: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics. J Rheumatol 1999; 26: 556-62
57. Yocum DE, Allard S, Cohen SB, et al. Microemulsion formulation of cyclosporia (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis: on behalf of the OLR 302 Study Group. Rheumatology 2000; 39: 156-64
58. Marchesoni A, Battafarano N, Arreghini M, et al. Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis. Arthritis Rheum 2002; 47: 59-66
59. Temekonidis TI, Georgiadis AN, Alamanos Y, et al. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis 2002; 61: 822-5
60. Cush JJ, Tugwell P, Weinblatt M, et al. US consensus guidelines for the use of cyclosporin A in rheumatoid arthritis. J Rheumatol 1999; 26: 1176-86
61. Furst DE, Saag K, Fleischmann MR, et al. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. Arthritis Rheum 2002; 46: 2020-8
62. Yocum D, Furst D, Kaine J, et al. Efficacy and safety of tacrolimus (Prograf; FK506) in the treatment of rheumatoid arthritis in patients who have failed one or more DMARDs [abstract]. Arthritis Rheum 2002; 46: S516
63. Yocum D, Furst D, Bensen W, et al. Long term safety of tacrolimus (Prograf: FK506) in the treatment of rheumatoid arthritis [abstract]. Arthritis Rheum 2002; 46: S540
64. Kremer J, Habros J, Kolba K, et al. Combination treatment with tacrolimus (Prograf; FK506) and methotrexate in rheumatoid arthritis patients who are partial responders to methotrexate [abstract]. Arthritis Rheum 2002; 46: S515